Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination antimicrobial preparation containing bacitracin, polymyxin B, and nystatin. This topical formulation provides broad-spectrum coverage against both bacterial and fungal infections. * **Bacitracin** inhibits bacterial cell wall synthesis. * **Polymyxin B** disrupts the outer cell membrane of Gram-negative bacteria by displacing calcium and magnesium ions from phosphates of membrane lipids, increasing membrane permeability and causing cytoplasmic leakage. * **Nystatin** is an antifungal agent that targets fungal infections, particularly those caused by Candida species. This combination is often used in compounded preparations for burn care and other skin infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bacitracin + polymyxin B + nystatin.